Skip to content

Arvinas ARVN Return on equity

Return on equity at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-61.4%-2.5pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-27.1%-3.7pp
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-32.6%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-48.8%-20.0pp
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
-154.4%+79.4pp
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-55.2%+8.0pp

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on trailing twelve months.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's return on equity?
Arvinas (ARVN) reported return on equity of -42.3% in Q1 2026.
How has Arvinas's return on equity changed year-over-year?
Arvinas's return on equity decreased by 476.0% year-over-year, from -7.3% to -42.3%.
What is the long-term trend for Arvinas's return on equity?
Over 5 years (2020 to 2025), Arvinas's return on equity has grown at a -10.0% compound annual growth rate (CAGR), from -27.5% to -16.2%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.